Change the course of treatment with Victoza® for your patients with T2D and established CVD
The LEADER CV outcomes trial showed Victoza® was proven to reduce CV risk1
The Victoza® patient*
See what patient types might benefit from a GLP-1 RA that reduces A1C and CV risk
Programs and resources are available to help support your adult patients with type 2 diabetes
- Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.